Results of a prospective phase 2 pilot trial of 177Lu–PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment …
L Emmett, M Crumbaker, B Ho, K Willowson… - Clinical genitourinary …, 2019 - Elsevier
Abstract Background 177 Lu–PSMA-617 (Lu-PSMA) is an emerging therapy in men with
metastatic castration-resistant prostate cancer. Paired theranostic agents have the potential
to visually identify phenotypes that will respond to targeted therapy. This study examined the
value of 68 Ga-HBEDD PSMA-11; prostate-specific membrane antigen (PSMA) positron
emission tomography (PET) in predicting treatment response and disease progression in Lu-
PSMA therapy within the context of a phase 2 prospective pilot trial. Patients and Methods …
metastatic castration-resistant prostate cancer. Paired theranostic agents have the potential
to visually identify phenotypes that will respond to targeted therapy. This study examined the
value of 68 Ga-HBEDD PSMA-11; prostate-specific membrane antigen (PSMA) positron
emission tomography (PET) in predicting treatment response and disease progression in Lu-
PSMA therapy within the context of a phase 2 prospective pilot trial. Patients and Methods …
以上显示的是最相近的搜索结果。 查看全部搜索结果